Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Intravenous Infusions's Total Liabilities for the quarter that ended in . 20 was GHS0.00 Mil. Intravenous Infusions's Total Assets for the quarter that ended in . 20 was GHS0.00 Mil.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Intravenous Infusions Liabilities-to-Assets Related Terms
Intravenous Infusions Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Intravenous Infusions's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Liabilities-to-Assets Chart
Intravenous Infusions Annual Data
Trend
Liabilities-to-Assets
Intravenous Infusions Semi-Annual Data
Liabilities-to-Assets
XGHA:IIL vs PTLF, PCYN, YBAO: Liabilities-to-Assets Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intravenous Infusions Liabilities-to-Assets vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Intravenous Infusions's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Intravenous Infusions's Liabilities-to-Assets Ratio for the fiscal year that ended in . 20 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions (XGHA:IIL) has a Liabilities-to-Assets of 0.00 as of . 20. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Intravenous Infusions and its competitors.
Is Intravenous Infusions' Liabilities-to-Assets too high?
Intravenous Infusions' current Liabilities-to-Assets is 0.00. Overall, Intravenous Infusions has a GF Score™ of 3/100, reflecting its overall financial health beyond just this single metric.
How does Intravenous Infusions' Liabilities-to-Assets compare to PTLF and PCYN?
Intravenous Infusions' Liabilities-to-Assets of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Intravenous Infusions and its competitors. Intravenous Infusions's current Liabilities-to-Assets is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Liabilities-to-Assets of 0.00. The current Liabilities-to-Assets is 0.00. Intravenous Infusions' overall GF Score™ is 3/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Liabilities-to-Assets is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
3GF Score
Get the complete analysis for XGHA:IIL
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:IIL has been successfully added to your 
